Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | IL-8 as a surrogate marker for pseudoprogression following anti-CD19 CAR-T in NHL

Arnon Nagler • 1 Feb 2021
TCT 2021
B-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma

Predicting responses following CAR T-cell therapy is of major importance. In this interview, Arnon Nagler, MD, of Chaim Sheba Medical Center, Tel-Aviv, Israel, evaluates the use of serum interleukin-8 (IL8) as a surrogate marker of true immediate tumor progression following CAR-T therapy in patients with non-Hodgkin lymphoma (NHL). This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals